TIXAGEVIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 08:53:30 GMT 2025` Edited by `admin` on `Wed Apr 02 08:53:30 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	F0LZ415Z3B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-8895

Preferred Name

English

TIXAGEVIMAB

Official Name

English

tixagevimab [INN]

Common Name

English

TIXAGEVIMAB [USAN]

Common Name

English

AZD8895

Code

English

COV2-2196

Code

English

IMMUNOGLOBULIN G1 (240-THREONINE,241-METHIONINE,308-TYROSINE,310-THREONINE,312-GLUTAMIC ACID), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL AZD8895 .GAMMA.1-CHAIN), DISULFIDE WITH HUM

Common Name

English

Tixagevimab [WHO-DD]

Common Name

English

TIXAGEVIMAB [JAN]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C177082

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

DAILYMED

F0LZ415Z3B

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

CAS

2420564-02-7

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

INN

11776

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

FDA UNII

F0LZ415Z3B

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

SMS_ID

300000026512

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

USAN

JK-66

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

RXCUI

2587300

Created by admin on Wed Apr 02 08:53:30 GMT 2025 , Edited by admin on Wed Apr 02 08:53:30 GMT 2025

PRIMARY

From	To
1_22	1_96
1_373	1_431
2_22	2_96
2_101	4_23
2_206	2_226
1_101	1_106
2_232	2_235
2_267	2_327
2_373	2_431
3_89	3_136
3_196	3_216
1_150	3_23
1_206	2_106
1_226	2_150
1_232	1_235
1_267	1_327

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_303
N	2_303

Related Record Type Details


					0EO1SV3LKY

SPIKE-1 PROTEIN SARS-COV-2

TARGET -> INHIBITOR

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					F0LZ415Z3B

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42
AMINO ACID REMOVAL	[1_453] [2_453]	C-TERMINUS			LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL